Trade News
Joint on-site project with Chongqing Chemical & Pharmaceutical Holding Company
Investment value: around EUR 200 million
Market position in China further strengthened
Munich, 3 May 2011 – The technology company The Linde Group will build and operate a large hydrogen and synthesis gas plant in the Chongqing Chemical Park in Western China in a joint enterprise with Chongqing Chemical & Pharmaceutical Holding Company (CCPHC). The project has a total investment value of around EUR 200 million. Linde holds 60 percent of the shares in the joint enterprise with CCPHC.
In future, the new on-site plant will provide the production facilities of BASF and CCPHC based in Chongqing with carbon monoxide, hydrogen and synthesis gas.
“We look forward to jointly supporting the expansion of the developing chemical cluster Chongqing with our partner CCPHC,” said Sanjiv Lamba, member of the Executive Board of Linde AG and responsible for the company’s business in Asia.“ As a result of this project, we will further strengthen our position as the leading gases and engineering company in the growth market China.”
The new plant, which will be supplied by Linde’s Engineering Division, is expected to come on stream in the third quarter of 2014.
The Linde Group is a world-leading gases and engineering company with around 48,700 employees in more than 100 countries worldwide. In the 2010 financial year, it achieved sales of EUR 12.868 bn. The strategy of The Linde Group is geared towards sustainable earnings-based growth and focuses on the expansion of its international business with forward-looking products and services. Linde acts responsibly towards its shareholders, business partners, employees, society and the environment – in every one of its business areas, regions and locations across the globe. Linde is committed to technologies and products that unite the goals of customer value and sustainable development.
For more information, see The Linde Group online at http://www.linde.com
Further information:
| Press Uwe Wolfinger Telephone: +49.89.35757-1320 |
Investor Relations Dr Dominik Heger Telephone: +49.89.35757-1334 Thomas Eisenlohr Telephone: +49.89.35757-1330 |